| Exploiting the folate receptor α in oncology M Scaranti, E Cojocaru, S Banerjee, U Banerji Nature reviews clinical oncology 17 (6), 349-359, 2020 | 372 | 2020 |
| Endocrine side effects of cancer immunotherapy P Cukier, FC Santini, M Scaranti, AO Hoff Endocrine-related cancer 24 (12), T331-T347, 2017 | 181 | 2017 |
| Emerging therapeutic targets in bladder cancer BA Carneiro, JJ Meeks, TM Kuzel, M Scaranti, SA Abdulkadir, FJ Giles Cancer Treatment Reviews 41 (2), 170-178, 2015 | 176 | 2015 |
| Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation versus chemoradiation for locally advanced cervical cancer: a randomized phase II trial SCS da Costa, RC Bonadio, FCG Gabrielli, AS Aranha, MLN Dias Genta, ... Journal of Clinical Oncology 37 (33), 3124-3131, 2019 | 82 | 2019 |
| Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: A single-centre, open-label, phase 1 … C Guo, M Chénard-Poirier, D Roda, M de Miguel, SJ Harris, IM Candilejo, ... The Lancet Oncology 21 (11), 1478-1488, 2020 | 52 | 2020 |
| Vitamin D and cancer: does it really matter? M Scaranti, G de Castro Júnior, AO Hoff Current Opinion in Oncology 28 (3), 205-209, 2016 | 28 | 2016 |
| Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy F Chamberlain, E Cojocaru, M Scaranti, J Noujaim, A Constantinou, ... Medical Oncology 37, 1-8, 2020 | 26 | 2020 |
| Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications CWS Wanderley, TS Correa, M Scaranti, FQ Cunha, R Barroso-Sousa Frontiers in Immunology 13, 816642, 2022 | 24 | 2022 |
| Radiological patterns of drug-induced interstitial lung disease (DILD) in early-phase oncology clinical trials A Terbuch, C Tiu, IM Candilejo, M Scaranti, A Curcean, D Bar, ... Clinical Cancer Research 26 (18), 4805-4813, 2020 | 20 | 2020 |
| CIC-DUX4 rearranged uterine cervix round-cell sarcoma exhibiting near-complete pathologic response following radiation and neoadjuvant chemotherapy: A case report AC Vieira, CB Xavier, TD Vieira, FM Carvalho, M Scaranti, RR Munhoz, ... Gynecologic Oncology Reports 36, 2021 | 13 | 2021 |
| Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma. JS Lopez, RS Kristeleit, R Rulach, NM Haris, M Scaranti, PJ Mulholland, ... Journal of Clinical Oncology 37 (15_suppl), 2025-2025, 2019 | 10 | 2019 |
| Response to paclitaxel in an adult patient with advanced Kaposiform hemangioendothelioma JM Mota, M Scaranti, LG Fonseca, DA Tolói, VP de Camargo, RR Munhoz, ... Case Reports in Oncology 9 (2), 481-487, 2016 | 7 | 2016 |
| Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation with cisplatin in locally advanced cervical cancer: A phase II, prospective, randomized, trial. S Silva, RRC Colombo Bonadio, F Gabrielli, AS Aranha, ML Genta, ... Journal of Clinical Oncology 36 (15_suppl), 5523-5523, 2018 | 5 | 2018 |
| Deep and sustained radiological response after MEK-RAF inhibition in HRAS mutant apocrine carcinoma of the scalp M Scaranti, DN Rodrigues, U Banerji European Journal of Cancer 122, 9-11, 2019 | 4 | 2019 |
| Breast and gynecologic cancers as a Brazilian health priority A Nogueira-Rodrigues, DD Rosa, DA Suzuki, E Paulino, LCG Landeiro, ... Revista da Associação Médica Brasileira 69 (suppl 1), e2023S120, 2023 | 3 | 2023 |
| Abstract CT140: Proof-of-concept evidence of immune modulation by blockade of the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway in the phase I dose escalation … JS Lopez, A Biondo, C Tiu, M Scaranti, M Ameratunga, A Zachariou, ... Cancer Research 80 (16_Supplement), CT140-CT140, 2020 | 3 | 2020 |
| Management of patients with recurrent/metastatic endometrial cancer: Consensus recommendations from an expert panel from Brazil DAP de Andrade, APG Guimarães, AC de Melo, A Nogueira-Rodrigues, ... Frontiers in Oncology 13, 1133277, 2023 | 1 | 2023 |
| The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis MFSA Ribeiro, CB Xavier, AAL Pereira, M Scaranti, LDBB Faria, ... Brazilian Journal of Oncology 18, 1-15, 2022 | 1 | 2022 |
| Clinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated phase I (P1) unit M Scaranti, R Caldwell, MS Miralles, R Shinde, A Pal, JE Ang, A Biondo, ... Annals of Oncology 30, v430, 2019 | 1 | 2019 |
| Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting outcome: A 10-year systematic review from the … A Terbuch, I Moreno Candilejo, M Scaranti, D Bar, M Estevez Timon, ... Journal of Clinical Oncology 37 (15_suppl), 3088-3088, 2019 | 1 | 2019 |
